Metastatik Renal Hücreli Kanser Hastalarında Genel Sağkalım Üzerine Etkili Faktörlerin İncelenmesi: Dokuz Eylül Üniversitesi Tıbbi Onkoloji Kliniği Örneği

Abstract

Aim: Despite many new generation treatments, it is known that the prognostic markers used to date
 in patients with metastatic renal cell carcinoma (mRCC), who have a very poor prognosis, can not accurately determine the prognosis in every patient. Therefore, the search for prognostic biomarkers continues. In this study, it was aimed to
 investigate the effect of pre-treatment biochemical parameters on oncological outcomes in mRHC patients.
 Material and Methods: We retrospectively evaluated the clinical, pathological, survival characteristics and factors affecting survival of 90
 mRCC patients who were metastatic (stage 4) or local (stage 1-3) at the time of diagnosis in our clinic, who underwent radical nephrectomy
 and relapsed during follow-up. Descriptive statistical analyzes of patients' demographic, clinicopathological and treatment characteristics
 were performed.
 Results: 21.2% of the patients were female and 78.8 % were male. There was no difference in median OS (overall survival) between women
 and men. The median OS duration was statistically significantly lower in patients with metastasis at the time of diagnosis (p=0.001). While the
 median OS was 36.2 months in metastatic patients at the time of diagnosis, the median OS was 90.4 months in patients with recurrence at
 follow-up. As the ratio of alkaline phosphatase/Albumin (ALP/ALB) increased, survival decreased (p=0.038). While the median OS of those
 with a CRP/ALB ratio of 0.072 (AUC.630
 p=0.046 cut off:0.072).
 Conclusion: It has been determined that the CRP/ALB ratio is a biomarker that determines the prognosis. We recommend immunotherapy
 in patients who progress after first-linetargettherapy. Today, prognosis has become important especially in the treatment decision of mRCC,
 and we think that our study will shedlight on the search for new prognostic markers.